Free Trial
NYSE:JNJ

Johnson & Johnson (JNJ) Stock Price, News & Analysis

$145.48
-1.00 (-0.68%)
(As of 07/8/2024 ET)
Today's Range
$145.25
$147.22
50-Day Range
$144.40
$154.68
52-Week Range
$143.13
$175.97
Volume
4.76 million shs
Average Volume
5.96 million shs
Market Capitalization
$350.12 billion
P/E Ratio
9.07
Dividend Yield
3.41%
Price Target
$174.07

Johnson & Johnson MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
19.7% Upside
$174.07 Price Target
Short Interest
Healthy
0.82% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.98
Upright™ Environmental Score
News Sentiment
0.87mentions of Johnson & Johnson in the last 14 days
Based on 24 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
2.73%
From $10.62 to $10.91 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.92 out of 5 stars

Medical Sector

28th out of 876 stocks

Pharmaceutical Preparations Industry

8th out of 416 stocks

JNJ stock logo

About Johnson & Johnson Stock (NYSE:JNJ)

Johnson & Johnson is a US-based multinational pharmaceutical company that started in the early 1870s. Robert Wood Johnson began training as a pharmacist at 16 and founded his 1st company in 1873. That company would be disbanded by 1886 when Johnson joined his brothers to form today's entity. The company’s first line of products was sterile surgical dressings which were soon followed up by household products and medical guides.

Today, Johnson & Johnson is one of the world’s largest companies. It is ranked 36th on the 2021 Fortune 500 list and is a Dow Jones Industrial Average member. The company operates via 250 subsidiaries with operations in 60 countries and product sales in 175. As of 2021, annual sales were in the range of $95 billion and growing. The company is also a leader in equality and the advancement of women’s rights. Johnson & Johnson’s workforce was nearly 50% female by 1910, and many held significant positions of responsibility.

Among the company’s many advances in health care is the advancement of sterile conditions to prevent postoperative and secondary infections. Products include sterile gauze, cotton and dressings, and the development of the industrial sterilization process. However, the product that launched the company to success was the combination of a sterile dressing with tape. The company called the new products Band-Aids, which is now synonymous with small, prepackaged bandages. Another major win for the company was Johnson & Johnson Baby Soap.

Today, Johnson & Johnson operates in 3 segments: Pharmaceutical, Consumer Health and MedTech. The Consumer Health segment alone covers brands like Aveeno, Listerine, Tylenol, Zyrtec, Band-Aid and Neosporin, which are among the world’s most recognizable brands. The company’s purpose is to “blend science and ingenuity to change the trajectory of health for humanity profoundly”.

The Pharmaceutical segment offers products in all segments of the healthcare spectrum and has partnerships to develop new drugs with at least 10 other major healthcare providers and dozens of smaller research facilities. Products are offered wholesale to retailers and through healthcare systems. The MedTech segment develops and manufactures various healthcare devices and diagnostic tools. Among the many recognizable products from this segment are ACUVUE contact lenses.

Johnson & Johnson went public in 1944 and began paying dividends soon after. The company began increasing its dividend payment in 1962 and has increased it yearly. The company is a member of the Dividend Aristocrat Index and qualifies as a Dividend King with more than 50 years of consecutive annual increases. The company employs more than 142,000 individuals and serves more than 1 billion daily. Regarding the company’s health, its track record of dividend payments is backed up by a AAA credit rating. Johnson & Johnson is one of only 2 US corporations with such a rating and is more trusted than the US government.

The company announced plans to split into two publicly traded companies in 2021. The move is expected to be complete in late 2023 and will result in a Consumer Health company and a Pharmaceutical company.





JNJ Stock Price History

JNJ Stock News Headlines

Pharmacist, scientist developing new medicines, medicaments, pharmacy, chemistry
AbbVie Stock: A Perfect Dip for Investors to Buy (JNJ)
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors
Background of Stock heatmap on the monitor in predominantly red
The Top 3 Sectors Poised For Growth This Summer (JNJ)
Communications, technology, and healthcare are the three hottest sectors for growth, but not all stocks will rise with the tides.
The only way to play the AI boom?
A new AI profit window is opening. But I believe if you want to take advantage of this next wave of AI … You have to do something very few people will have the courage to do.
7 Diversified Income Powerhouses for Lifelong Cash Flow
7 Diversified Income Powerhouses for Lifelong Cash Flow
3 Rock-Solid Income Machines to Hold for Decades
The only way to play the AI boom?
A new AI profit window is opening. But I believe if you want to take advantage of this next wave of AI … You have to do something very few people will have the courage to do.
7 Blue-Chip Cash Cows to Milk for Steady Income
Johnson & Johnson (NYSE:JNJ) Shares Up 0.4%
See More Headlines
Receive JNJ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/16/2024
Ex-Dividend for 6/4 Dividend
5/20/2024
Dividend Payable
6/04/2024
Today
7/08/2024
Next Earnings (Confirmed)
7/17/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
47816010
Employees
131,900
Year Founded
1886

Price Target and Rating

Average Stock Price Target
$174.07
High Stock Price Target
$215.00
Low Stock Price Target
$160.00
Potential Upside/Downside
+19.7%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
13 Analysts

Profitability

Net Income
$35.15 billion
Pretax Margin
22.38%

Debt

Sales & Book Value

Annual Sales
$85.65 billion
Cash Flow
$13.57 per share
Book Value
$28.57 per share

Miscellaneous

Outstanding Shares
2,406,679,000
Free Float
2,402,828,000
Market Cap
$350.12 billion
Optionable
Optionable
Beta
0.52

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Should I Buy Johnson & Johnson Stock? JNJ Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Johnson & Johnson:

  • Johnson & Johnson reported earnings per share of $2.71 for the quarter, beating analysts' estimates by $0.07. This indicates strong financial performance and potential for growth.
  • The company increased its dividend, with a quarterly dividend of $1.24 per share, representing a dividend yield of 3.38%. This can be attractive for income-seeking investors.
  • Institutional investors like SteelPeak Wealth LLC have been increasing their stake in Johnson & Johnson, indicating confidence in the company's future prospects.
  • Johnson & Johnson has a market cap of $351.45 billion, reflecting its position as a large and stable company in the healthcare industry.
  • The stock price of Johnson & Johnson has shown resilience, with a 52-week low of $143.13 and a 52-week high of $175.97, providing potential for capital appreciation.

Cons

Investors should be bearish about investing in Johnson & Johnson for these reasons:

  • Johnson & Johnson's 50-day moving average is $148.09, below the 200-day moving average of $153.97, indicating a short-term bearish trend in the stock price.
  • The company's PEG ratio of 2.43 may suggest that the stock is overvalued relative to its earnings growth potential, which could deter value-oriented investors.
  • While Johnson & Johnson has a strong dividend history, the dividend payout ratio of 30.92% may limit future dividend growth opportunities.
  • The company's beta of 0.52 indicates lower volatility compared to the market, potentially leading to lower returns during bullish market conditions.
  • Johnson & Johnson's debt-to-equity ratio of 0.36 may raise concerns about the company's leverage and financial risk management.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 7, 2024. Please send any questions or comments about these Johnson & Johnson pros and cons to contact@marketbeat.com.

JNJ Stock Analysis - Frequently Asked Questions

How have JNJ shares performed this year?

Johnson & Johnson's stock was trading at $156.74 at the beginning of the year. Since then, JNJ stock has decreased by 7.2% and is now trading at $145.48.
View the best growth stocks for 2024 here
.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) posted its quarterly earnings results on Tuesday, April, 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson's quarterly revenue was up 2.3% on a year-over-year basis.
Read the conference call transcript
.

Is Johnson & Johnson doing a stock buyback?

Johnson & Johnson's board approved a share repurchase program on Wednesday, September 14th 2022, which permits the company to buy back $5,000,000,000 in shares, according to EventVestor. This means that the company could buy up to 1.2% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board of directors believes its shares are undervalued.

What is Alex Gorsky's approval rating as Johnson & Johnson's CEO?

2,535 employees have rated Johnson & Johnson Chief Executive Officer Alex Gorsky on Glassdoor.com. Alex Gorsky has an approval rating of 94% among the company's employees. This puts Alex Gorsky in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Does Johnson & Johnson have any subsidiaries?

Johnson & Johnson subsidiaries include these companies: Momenta Pharmaceuticals, TARIS Biomedical, Verb Surgical, Auris Health, Ci:z Holdings, Zarbee's Naturals, Orthotaxy, and more.

Who are Johnson & Johnson's major shareholders?

Johnson & Johnson's top institutional investors include DNB Asset Management AS (0.06%), Douglas Lane & Associates LLC (0.02%), Armstrong Henry H Associates Inc. (0.02%) and Massmutual Trust Co. FSB ADV (0.01%). Insiders that own company stock include & Johnson Johnson, Jennifer L Taubert, Peter Fasolo, William Hait, Kathryn E Wengel, Ashley Mcevoy, Thibaut Mongon, Joseph J Wolk, Robert J Decker and James D Swanson.
View institutional ownership trends
.

How do I buy shares of Johnson & Johnson?

Shares of JNJ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Johnson & Johnson own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Johnson & Johnson investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Walt Disney (DIS), NVIDIA (NVDA), Intel (INTC) and JPMorgan Chase & Co. (JPM).

This page (NYSE:JNJ) was last updated on 7/9/2024 by MarketBeat.com Staff

From Our Partners